MiMedx Group, Inc. (NASDAQOTH:MDXG)

CAPS Rating: 1 out of 5

Caps

How do you think MDXG will perform against the market?

Add Stock to CAPS Watchlist

All Players

42 Outperform
16 Underperform
 

All-Star Players

11 Outperform
9 Underperform
 

Wall Street

2 Outperform
0 Underperform
 

Top MDXG Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Bigsef77 (68.03)
Submitted September 20, 2018

MiMedx Announces Statistically Significant Results In New Multicenter Clinical Study Of Healing Of Diabetic Foot Ulcers Using EpiFix®PR Newswire PR Newswire•August 24, 2018- Study Published in International Wound Journal Reported Statistically… More

volfan84 (74.90)
Submitted July 19, 2018

Apparently MiMedx Group was engaged in quite a bit of fraud. Their CEO recently left, and the interim CEO brought in was previously the interim CFO for Lehman Brothers when they were going through their bankruptcy, if I'm not mistaken. Today's bump… More

MDXG VS S&P 500 (SPY)

Fools bullish on MDXG are also bullish on:

Fools bearish on MDXG are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about MDXG.

Recs

1
Member Avatar Bigsef77 (68.03) Submitted: 9/20/2018 4:03:52 PM : Outperform Start Price: $4.45 MDXG Score: -55.71

MiMedx Announces Statistically Significant Results In New Multicenter Clinical Study Of Healing Of Diabetic Foot Ulcers Using EpiFix®
PR Newswire PR Newswire•August 24, 2018
- Study Published in International Wound Journal Reported Statistically Significant Evidence of Healing Compared to Control Group

- Intent-To-Treat EpiFix Treated Patients = 70% vs Control 50%, p=0.0338

- Per-Protocol EpiFix Treated Patients = 81% vs Control 55%, p=0.0093

MARIETTA, Ga., Aug. 24, 2018 /PRNewswire/ -- MiMedx Group, Inc. (MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today announced that a new study regarding the use of EpiFix® in the treatment of diabetic foot ulcers (DFUs) has been published in the peer-reviewed journal, International Wound Journal.

The paper is entitled "A Confirmatory Study on the Efficacy of Dehydrated Human Amnion/Chorion Membrane dHACM Allograft in the Management of Diabetic Foot Ulcers: A Prospective, Multicenter, Randomized, Controlled Study of 110 Patients from 14 Wound Clinics." The paper was authored by: William Tettelbach, MD; Shawn Cazzell, DPM; Alexander M. Reyzelman, DPM; Felix Sigal, DPM; Joseph M Caporusso, DPM; and Patrick S. Agnew, DPM. The electronic publication of the article in International Wound Journal can be found

Recs

1
Member Avatar XMFRendezvous (91.84) Submitted: 7/23/2018 10:05:41 PM : Underperform Start Price: $3.82 MDXG Score: +51.12

SEC is knocking.

Recs

2
Member Avatar volfan84 (74.90) Submitted: 7/19/2018 5:53:13 PM : Underperform Start Price: $4.13 MDXG Score: +54.83

Apparently MiMedx Group was engaged in quite a bit of fraud. Their CEO recently left, and the interim CEO brought in was previously the interim CFO for Lehman Brothers when they were going through their bankruptcy, if I'm not mistaken. Today's bump of just under 18% (on July 19th, 2018) should give a nice additional boost for me if this one does end up going bankrupt and the equity becoming worthless. I have a real-world position of Aug. 17, 2018 $2.50 puts for this as well.

Leaderboard

Find the members with the highest scoring picks in MDXG.

Score Leader

glenn12345

glenn12345 (99.99) Score: +136.44

The Score Leader is the player with the highest score across all their picks in MDXG.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
soonerbear98 < 20 10/3/2013 Underperform 5Y $4.52 -65.71% +53.08% +118.79 0 Comment
vj507 40.70 2/10/2015 Underperform 5Y $8.24 -81.19% +25.62% +106.81 0 Comment
oldwickdave < 20 2/10/2017 Underperform 3M $8.17 -81.03% +11.86% +92.89 1 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. chammond55 98.01 2/20/2018 Underperform 5Y $9.05 -82.87% -5.18% +77.69 0 Comment
sn0wf0g < 20 5/29/2018 Underperform 1Y $8.29 -81.30% -3.87% +77.43 0 Comment
PAGEBOY73 99.16 5/16/2018 Underperform NS $7.19 -78.44% -5.19% +73.25 0 Comment
OttoBismarck 99.94 11/5/2018 Underperform 5Y $6.40 -75.78% -5.16% +70.62 0 Comment
zulabu < 20 10/25/2018 Underperform 3M $5.13 -69.79% -3.36% +66.42 0 Comment
wallet2061 72.65 9/10/2018 Underperform 5Y $5.49 -71.77% -10.51% +61.26 0 Comment
RyanIdaho 96.23 9/14/2018 Underperform 5Y $4.95 -68.69% -11.22% +57.46 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackJimCramer 85.22 10/20/2015 Outperform 3W $8.89 -82.56% +27.23% -109.79 0 Comment
TrackJimCramer 85.22 8/10/2015 Underperform 3W $9.37 -5.12% -3.58% +1.54 10/20/2015 @ $8.89 0 Comment
TrackJimCramer 85.22 5/29/2015 Outperform 3W $10.35 -9.47% -0.24% -9.23 8/10/2015 @ $9.37 0 Comment
TrackCanaccord 69.06 12/20/2013 Outperform NS $7.77 -80.05% +43.02% -123.07 0 Comment

Advertisement